Salmonellosis medical therapy: Difference between revisions

	Salmonellosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Salmonellosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Salmonellosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Salmonellosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Salmonellosis medical therapy
CDC on Salmonellosis medical therapy
Salmonellosis medical therapy in the news
Blogs on Salmonellosis medical therapy
Directions to Hospitals Treating Salmonellosis
Risk calculators and risk factors for Salmonellosis medical therapy

VisualWikitext

Latest revision as of 18:41, 18 September 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]

Overview

The majority of cases of uncomplicated salmonellosis are self-limited and only require supportive care. Supportive therapy for salmonellosis includes elctrolyte replacement, rehydration, and adequate nutrition. Symptomatic treatment includes either Loperamide or Bismuth subsalicylate. Antimicrobial therapy is indicated in infants, elderly patients, immunocompromised patients, and patients with severe disease. Antimicrobial therapy for salmonellosis may include either Trimethoprim-sulfamethoxazole, fluoroquinolones, or Ceftriaxone.

Medical Therapy

Mild cases of salmonelloses usually resolve within 5 to 7 days. Patients with severe cases of the disease may require rehydration with intravenous fluids. Antibiotic treatment is not routinely recommended, unless the patient becomes severely dehydrated, belongs to one of the risk groups described below, or the infection reaches the blood stream.^[1]

Salmonellosis commonly presents with unspecific gastrointestinal symptoms, such as diarrhea, fever, and abdominal pain. Antibiotic treatment of infectious diarrhea is considered controversial because:^[2]

Symptoms may be caused by different types of enteric pathogens, what makes the initial treatment of severe cases often "empiric"
Antibiotic treatment of non-typhoidal salmonellosis prolongs shedding of the bacteria in feces

Supportive Therapy

Initial therapy of infectious diarrhea, irrespectively to the causative agent, should start with rehydration. Oral rehydration with a glucose and electrolyte solution is preferred, except in cases where the patient is severely dehydrated or comatose. ^[3]

Nutritional support should also be provided, particularly in children, where it was shown to improve outcomes. The use of the "BRAT diet" is also frequently recommended. This diet consists of bananas, rice, applesauce and toast, with avoidance of dairy products, due to the potential deficiency of lactase, following the gastrointestinal disturbance.^[3]^[4]

Symptomatic Therapy

Although there is little evidence of the efficacy of most of the antidiarrheal agents on the marker, the following have demonstrated to be effective in controlled, randomized trials:^[3]^[5]

Loperamide

Antimotility agent, with anti-secretory properties, able to inhibit intestinal peristalsis. Despite being an opiate, it does not have the potential of addiction, since it does not penetrate the nervous system.^[6]

Loperamide should be avoided in patients with inflammatory or bloody diarrhea because of the relation between antimotility agents and prolonged fever in patients infected with Shigella and C. difficile (other potential causative agents of infectious diarrhea).^[7]

Bismuth Subsalicylate

Bismuth subsalicylate may alleviate symptoms such as: nausea, diarrhea and abdominal pain.^[8] It was also shown to decrease stool output in pediatric patients.^[9]

Antibiotic Therapy

Indications

Antibiotics are not recommended for uncomplicated salmonellosis because they prolong shedding of the bacteria, typically do not alleviate the diarrhea, and have been associated with relapse.^[3]^[10]^[11] Antibiotic therapy is only indicated for patients with severe cases of the disease, and for those with risk factors for extra-intestinal infection, after blood and fecal cultures have been obtained. Risk groups for the development of severe disease, and extra-intestinal manifestations include:^[2]^[3]^[12]

Infants and elderly
Patients with pernicious anemia
Patients taking H2 antagonists and antacids
Changes in endogenous bowel flora, in:
- Surgery
- Recent antibiotic treatment
Diabetes
HIV infection
Malignancy
Valvular heart disease
Rheumatological diseases
Blockage of reticuloendothelial system
Transplant recipients
Immunosuppressive therapy
Lymphoprolipherative disease
Hemoglobinopathies
Prosthetic devices, such as artificial joints

Antibiotic treatment may be indicated in cases when rapid interruption of fecal shedding of the bacteria is required to avoid outbreaks in institutions.^[13]

Antimicrobial regimen

1. Salmonellosis in immunocompetent hosts^[14]

1.1 Gastroenteritis

Antimicrobial therapy is usually not recommended for uncomplicated diarrheal illness.
1.1.1 Indications for antimicrobial therapy

severedisease,
Age > 50 yrs
Prosthesis
Presence of valvular heart disease
Severe atherosclerosis
Cancer
Uremia
Immunosuppression

1.1.2 Treatment regimens

Preferred regimen (1): TMP-SMX DS PO bid for 5-7 days
Preferred regimen (2): Ciprofloxacin 500 mg PO bid for 5-7 days
Preferred regimen (3): Ceftriaxone 2 g IV q24h for 5-7 days

1.2 Typhoid fever^[15]

1.2.1 Uncomplicated typhoid

Preferred regimen (1) (fully susceptible): Fluoroquinolone (e.g., Ofloxacin 15 mg/kg PO qd for 5–7 days)
Preferred regimen (2) (multi drug-resistant): Fluoroquinolone (Ofloxacin 15 mg/kg PO qd for 5–7 days)
Preferred regimen (3) (quinolone-resistant): Azithromycin 8–10 mg/kg PO qd for 7 days
Preferred regimen (4) (quinolone-resistant): Fluoroquinolone 20 mg/kg PO qd for 10-14 days
Alternative regimen (1) (fully susceptible): Chloramphenicol 50–75 mg/kg PO qd for 14-21 days
Alternative regimen (2) (fully susceptible): Amoxicillin 75–100 mg/kg PO qd for 14 days
Alternative regimen (3) (fully susceptible): Trimethoprim–Sulfamethoxazole, 8 mg/kg (trimethoprim)– 40 mg/kg (sulfamethoxazole) PO qd for 14 days
Alternative regimen (4) (multi drug-resistant): Azithromycin 8–10 mg/kg PO for 7 days
Alternative regimen (5) (multi drug-resistant): Third-generation cephalosporin, e.g., Cefixime 20 mg/kg PO qd for 7-14 days
Alternative regimen (6) (quinolone-resistant): Third-generation cephalosporin, e.g., Cefixime 20 mg/kg PO qd for 7-14 days

1.2.2 Severe typhoid

Preferred regimen (1) (fully susceptible): Fluoroquinolone (e.g., Ofloxacin 15 mg/kg IV qd for 10-14 days)
Preferred regimen (2) (multi drug-resistant): Fluoroquinolone (Ofloxacin 15 mg/kg IV qd for 10-14 days)
Preferred regimen (3) (quinolone-resistant): Ceftriaxone 60 mg/kg IV qd for 10-14 days
Preferred regimen (4) (quinolone-resistant): Cefotaxime 80 mg/kg IV qd for 10-14 days
Alternative regimen (1) (fully susceptible): Chloramphenicol 100 mg/kg PO qd for 14-21 days
Alternative regimen (2) (fully susceptible): Ampicillin 100 mg/kg PO qd for 14-21 days
Alternative regimen (3) (fully susceptible): Trimethoprim–Sulfamethoxazole, 8 mg/kg (trimethoprim)– 40 mg/kg (sulfamethoxazole) IV qd for 10-14 days
Alternative regimen (4) (multi drug-resistant): Ceftriaxone 60 mg/kg IV qd for 10-14 days
Alternative regimen (5) (multi drug-resistant): Cefotaxime 80 mg/kg IV qd for 10-14 days
Alternative regimen (6) (quinolone-resistant): Fluoroquinolone 20 mg/kg IV qd for 10-14 days

1.3 Non-typhoid (serious infection)^[16]

Preferred regimen (1): 3rd generation cephalosporin (Ceftriaxone/Cefotaxime)
Preferred regimen (2): Fluoroquinolone (Ciprofloxacin, Levofloxacin)

1.4 Bacteremia^[17]

Preferred regimen (1): Ceftriaxone 2 g IV q24h

Preferred regimen (2): Cefotaxime 2 g IV q6-8h for 7-14 days

Preferred regimen (3): Ciprofloxacin 400 mg IV q12h for 7-14 days

1.5 Vascular prosthesis infection^[18]

Preferred regimen (1): Ceftriaxone

Preferred regimen (2): Cefotaxime

Preferred regimen (3): Ciprofloxacin 400 mg IV q12h for 6 weeks

1.6 Osteomyelitis^[19]

Preferred regimen (1): Ceftriaxone 2 g IV q24h

Preferred regimen (2): Cefotaxime 2 g IV q6-8h

Preferred regimen (3): Ciprofloxacin 750 mg PO bid for ≥ 4 weeks

1.7 Arthritis^[20]

Preferred regimen (1): Ceftriaxone 2 g IV q24h

Preferred regimen (2): Cefotaxime 2 g IV q6-8h for 6 weeks

1.8 Endocarditis^[21]

Preferred regimen (1): Ceftriaxone 2 g IV q24h

Preferred regimen (2): Cefotaxime 2 g IV q6-8h for 6 weeks

1.9 UTI^[22]

Preferred regimen (1): Ceftriaxone

Preferred regimen (2): Cefotaxime

Preferred regimen (3): Ciprofloxacin IV for 1-2 weeks THEN (oral Ciprofloxacin OR TMP-SMX for 6 weeks)

1.10 Carrier state^[23]

Preferred regimen (1): Ciprofloxacin 500 mg PO bid for 4-6 weeks
Preferred regimen (2): TMP-SMX 1DS bid PO for 6 weeks
Preferred regimen (3): Amoxicillin 500 mg PO for 6 weeks

2. Salmonellosis in immunocompromised hosts

2.1 HIV and salmonellosis^[24]

2.1.1 Gastroenteritis

Preferred regimen: Ciprofloxacin 500-750 mg PO bid or 400 mg IV q12h, if susceptible
Alternative regimen (1): Levofloxacin 750 mg PO/IV q24h
Alternative regimen (2): Moxifloxacin 400 mg PO/IV q24h
Alternative regimen (3): TMP 160 mg AND SMX 800 mg PO/IV q12h
Alternative regimen (4): Ceftriaxone 1 g IV q24h
Alternative regimen (5): Cefotaxime 1 g IV q8h
Duration of treatment for gastroenteritis without bacteremia

If CD4 count ≥ 200 cells/μL: Duration of treatment is 7–14 days
If CD4 count < 200 cells/μL: Duration of treatment is 2–6 weeks

Duration of treatment for gastroenteritis with bacteremia

If CD4 count ≥ 200/μL: Duration of treatment is 14 days; longer duration if bacteremia persists or if the infection is complicated (e.g., if metastatic foci of infection are present)
If CD4 count < 200 cells/μL: Duration of treatment is 2–6 weeks

Note (1): Secondary prophylaxis should be considered for

Patients with recurrent Salmonella gastroenteritis with or without bacteremia
Patients with CD4 < 200 cells/μL with severe diarrhea

1. Salmonella bacteremia treatment

Preferred regimen: Ciprofloxacin 400 mg IV q12h AND Ceftriaxone 1 to 2 g IV q12-24h^[25]

2.When the salmonellae are known to be susceptible

Preferred regimen: Ampicillin 1 to 2 g IV q4-6h
Preferred regimen: Trimethoprim-sulfamethoxazole 8 mg/kg/day PO

\====Recommended Agents==== For the cases where antibiotics are indicated, treatment should include one of the following:^[3]^[26]

Trimethoprim-Sulfamethoxazole

Indicated for children, and when susceptibility is suspected

Children
5 mg/kg (trimethoprim) + 25 mg/kg (sulfamethoxazole) twice/day, during 3 days
Adults
160 mg (trimethoprim) + 800 mg (sulfamethoxazole) twice/day, during 3 days

Fluoroquinolones

Adults
Ciprofloxacin - 500 mg PO twice/day, during 1 to 3 days
Norfloxacin - 400 mg PO twice/day, during 1 to 3 days
Levofloxacin - 500 mg PO once/day, during 1 to 3 days
Ofloxacin - 300 mg twice/day, during 1 to 3 days

Ceftriaxone

Children <12 years old
50-75 mg/kg body weight/day in 1 or 2 doses
Adults
100 mg/Kg body weight/day in 1 or 2 doses

For immunocompromised patients, the duration of the antibiotic treatment described above should be prolonged for 14 days, or longer in case of relapse.^[26]

Multidrug Resistance

Some serovars of Salmonella enterica, particularly Typhimurium and Newport, are linked to more severe cases of salmonellosis and multi-drug resistance.^[12]

Follow Up

Fecal cultures are not indicated for patient follow-up after uncomplicated cases of salmonellosis, irrespectively to the treatment administrated. The results tend to be intermittently positive for a long period of time, and do not show any utility in asymptomatic patients.^[2]^[27]

References

↑ "Salmonella (non-typhoidal)".
↑ ^2.0 ^2.1 ^2.2 Hohmann EL (2001). "Nontyphoidal salmonellosis". Clin Infect Dis. 32 (2): 263–9. doi:10.1086/318457. PMID 11170916.
↑ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 Thielman NM, Guerrant RL (2004). "Clinical practice. Acute infectious diarrhea". N Engl J Med. 350 (1): 38–47. doi:10.1056/NEJMcp031534. PMID 14702426.
↑ "Managing Acute Gastroenteritis Among Children Oral Rehydration, Maintenance, and Nutritional Therapy".
↑ "Antidiarrheal Drug Products for Over-the-Counter Human Use; Amendment of Final Monograph".
↑ DuPont HL, Flores Sanchez J, Ericsson CD, Mendiola Gomez J, DuPont MW, Cruz Luna A; et al. (1990). "Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea". Am J Med. 88 (6A): 15S–19S. PMID 2192553.
↑ DuPont HL, Hornick RB (1973). "Adverse effect of lomotil therapy in shigellosis". JAMA. 226 (13): 1525–8. PMID 4587313.
↑ DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB (1977). "Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university". Gastroenterology. 73 (4 Pt 1): 715–8. PMID 330307.
↑ Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, León-Barúa R, Sarabia-Arce S, Campos-Sánchez M; et al. (1993). "A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease". N Engl J Med. 328 (23): 1653–8. doi:10.1056/NEJM199306103282301. PMID 8487823.
↑ Wiström J, Jertborn M, Ekwall E, Norlin K, Söderquist B, Strömberg A; et al. (1992). "Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group". Ann Intern Med. 117 (3): 202–8. PMID 1616214.
↑ Neill MA, Opal SM, Heelan J, Giusti R, Cassidy JE, White R; et al. (1991). "Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers". Ann Intern Med. 114 (3): 195–9. PMID 1898630.
↑ ^12.0 ^12.1 Gal-Mor O, Boyle EC, Grassl GA (2014). "Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ". Front Microbiol. 5: 391. doi:10.3389/fmicb.2014.00391. PMID 25136336.
↑ Lightfoot NF, Ahmad F, Cowden J (1990). "Management of institutional outbreaks of Salmonella gastroenteritis". J Antimicrob Chemother. 26 Suppl F: 37–46. PMID 2292544.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ "TYPHOID FEVER".
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
↑ "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF).
↑ Goldman, Lee (2012). Goldman's Cecil Medicine, Twenty-Fourth Edition. Saunders, an imprint of Elsevier Inc. ISBN 978-1-4377-1604-7.
↑ ^26.0 ^26.1 Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.
↑ Buchwald DS, Blaser MJ (1984). "A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella". Rev Infect Dis. 6 (3): 345–56. PMID 6377442.

Template:WikiDoc Sources

[WHO-1] "Salmonella (non-typhoidal)".

[pmid11170916-2] 2.0 ^2.1 ^2.2 Hohmann EL (2001). "Nontyphoidal salmonellosis". Clin Infect Dis. 32 (2): 263–9. doi:10.1086/318457. PMID 11170916.

[pmid14702426-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 Thielman NM, Guerrant RL (2004). "Clinical practice. Acute infectious diarrhea". N Engl J Med. 350 (1): 38–47. doi:10.1056/NEJMcp031534. PMID 14702426.

[MMWR-4] "Managing Acute Gastroenteritis Among Children Oral Rehydration, Maintenance, and Nutritional Therapy".

[FDA-5] "Antidiarrheal Drug Products for Over-the-Counter Human Use; Amendment of Final Monograph".

[pmid2192553-6] DuPont HL, Flores Sanchez J, Ericsson CD, Mendiola Gomez J, DuPont MW, Cruz Luna A; et al. (1990). "Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea". Am J Med. 88 (6A): 15S–19S. PMID 2192553.

[pmid4587313-7] DuPont HL, Hornick RB (1973). "Adverse effect of lomotil therapy in shigellosis". JAMA. 226 (13): 1525–8. PMID 4587313.

[pmid330307-8] DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB (1977). "Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university". Gastroenterology. 73 (4 Pt 1): 715–8. PMID 330307.

[pmid8487823-9] Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, León-Barúa R, Sarabia-Arce S, Campos-Sánchez M; et al. (1993). "A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease". N Engl J Med. 328 (23): 1653–8. doi:10.1056/NEJM199306103282301. PMID 8487823.

[pmid1616214-10] Wiström J, Jertborn M, Ekwall E, Norlin K, Söderquist B, Strömberg A; et al. (1992). "Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group". Ann Intern Med. 117 (3): 202–8. PMID 1616214.

[pmid1898630-11] Neill MA, Opal SM, Heelan J, Giusti R, Cassidy JE, White R; et al. (1991). "Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers". Ann Intern Med. 114 (3): 195–9. PMID 1898630.

[pmid25136336-12] 12.0 ^12.1 Gal-Mor O, Boyle EC, Grassl GA (2014). "Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ". Front Microbiol. 5: 391. doi:10.3389/fmicb.2014.00391. PMID 25136336.

[pmid2292544-13] Lightfoot NF, Ahmad F, Cowden J (1990). "Management of institutional outbreaks of Salmonella gastroenteritis". J Antimicrob Chemother. 26 Suppl F: 37–46. PMID 2292544.

[14] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[15] "TYPHOID FEVER".

[16] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[17] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[18] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[19] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[20] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[21] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[22] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[23] Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.

[24] "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF).

[25] Goldman, Lee (2012). Goldman's Cecil Medicine, Twenty-Fourth Edition. Saunders, an imprint of Elsevier Inc. ISBN 978-1-4377-1604-7.

[pmid11170940-26] 26.0 ^26.1 Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.

[pmid6377442-27] Buchwald DS, Blaser MJ (1984). "A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella". Rev Infect Dis. 6 (3): 345–56. PMID 6377442.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

@@ Line 4: / Line 4: @@
 ==Overview==
+The majority of cases of uncomplicated salmonellosis are self-limited and only require supportive care.  Supportive therapy for salmonellosis includes elctrolyte replacement, [[rehydration]], and adequate [[nutrition]]. Symptomatic treatment includes either [[Loperamide]] or [[Bismuth subsalicylate]]. [[Antimicrobial]] therapy is indicated in infants, elderly patients, immunocompromised patients, and patients with severe disease.  Antimicrobial therapy for salmonellosis may include either [[Trimethoprim-sulfamethoxazole]], [[fluoroquinolones]], or [[Ceftriaxone]].
 ==Medical Therapy==
-Treatment of salmonellosis is often symptomatic, with electrolyte replacement and rehydration. Mild cases of salmonelloses usually resolve within 5 to 7 days. Patients with severe cases of the disease may require [[rehydration]], often with [[intravenous fluids]]. [[Antibiotic]] treatment is not routinely recommended, unless the patient becomes severely [[dehydrated]] or [[infection]] reaches the [[blood stream]].<ref name=WHO>{{cite web | title = Salmonella (non-typhoidal) | url = http://www.who.int/mediacentre/factsheets/fs139/en/ }}</ref>
+Mild cases of salmonelloses usually resolve within 5 to 7 days. Patients with severe cases of the disease may require [[rehydration]] with [[intravenous fluids]]. [[Antibiotic]] treatment is not routinely recommended, unless the patient becomes severely [[dehydrated]], belongs to one of the risk groups described below, or the [[infection]] reaches the [[blood stream]].<ref name=WHO>{{cite web | title = Salmonella (non-typhoidal) | url = http://www.who.int/mediacentre/factsheets/fs139/en/ }}</ref>
 [[Salmonellosis]] commonly presents with unspecific [[gastrointestinal]] symptoms, such as [[diarrhea]], [[fever]], and [[abdominal pain]]. [[Antibiotic]] treatment of infectious [[diarrhea]] is considered controversial because:<ref name="pmid11170916">{{cite journal| author=Hohmann EL| title=Nontyphoidal salmonellosis. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 2 | pages= 263-9 | pmid=11170916 | doi=10.1086/318457 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170916  }} </ref>
-*[[Symptoms]] may be caused by different types of [[enteric]] pathogens, which makes the initial treatment of severe cases often "empiric"
+*[[Symptoms]] may be caused by different types of [[enteric]] pathogens, what makes the initial treatment of severe cases often "empiric"
-*[[Antibiotic]] treatment of non-typhoidal salmonellosis prolongs shedding of the [[bacteria]] in feces.
+*[[Antibiotic]] treatment of non-typhoidal salmonellosis prolongs shedding of the [[bacteria]] in feces
-===Supportive Treatment===
+===Supportive Therapy===
-Initial therapy of infectious diarrhea, irrespectively from the causative agent, should start with rehydration. Oral [[rehydration]] with a [[glucose]] and [[electrolyte]] solution is preferred, except in cases where the patient is severely [[dehydrated]] or [[comatose]]. <ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref>
+Initial therapy of infectious [[diarrhea]], irrespectively to the causative agent, should start with [[rehydration]]. Oral [[rehydration]] with a [[glucose]] and [[electrolyte]] solution is preferred, except in cases where the patient is severely [[dehydrated]] or [[comatose]]. <ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref>
-Nutritional support should also be provided, particularly in children, where it was shown to improve outcomes. The use of the ''"BRAT diet"'' is also frequently recommended. This diet consists in bananas, rice, applesauce and toast, with avoidance of dairy products, due to the potential deficiency of [[lactase]] following the [[gastrointestinal]] disturbance.<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name=MMWR>{{cite web | title = Managing Acute Gastroenteritis Among Children Oral Rehydration, Maintenance, and Nutritional Therapy | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5216a1.htm }}</ref>
+Nutritional support should also be provided, particularly in children, where it was shown to improve outcomes. The use of the ''"BRAT diet"'' is also frequently recommended. This diet consists of bananas, rice, applesauce and toast, with avoidance of dairy products, due to the potential deficiency of [[lactase]], following the [[gastrointestinal]] disturbance.<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name=MMWR>{{cite web | title = Managing Acute Gastroenteritis Among Children Oral Rehydration, Maintenance, and Nutritional Therapy | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5216a1.htm }}</ref>
-===Symptomatic Treatment===
+===Symptomatic Therapy===
 Although there is little evidence of the efficacy of most of the [[antidiarrheal]] agents on the marker, the following have demonstrated to be effective in controlled, randomized trials:<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name=FDA>{{cite web | title = Antidiarrheal Drug Products for Over-the-Counter Human Use; Amendment of Final Monograph | url = https://www.federalregister.gov/articles/2004/05/12/04-10750/antidiarrheal-drug-products-for-over-the-counter-human-use-amendment-of-final-monograph }}</ref>
-====Loperamide====
+* '''Loperamide'''
-Antimotility agent, with anti-secretory properties, able to inhibit intestinal [[peristalsis]]. Despite being an [[opiate]], it does not have the potential of addiction, because it does not penetrate the [[nervous system]].<ref name="pmid2192553">{{cite journal| author=DuPont HL, Flores Sanchez J, Ericsson CD, Mendiola Gomez J, DuPont MW, Cruz Luna A et al.| title=Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. | journal=Am J Med | year= 1990 | volume= 88 | issue= 6A | pages= 15S-19S | pmid=2192553 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2192553  }} </ref>
+Antimotility agent, with anti-secretory properties, able to inhibit intestinal [[peristalsis]]. Despite being an [[opiate]], it does not have the potential of addiction, since it does not penetrate the [[nervous system]].<ref name="pmid2192553">{{cite journal| author=DuPont HL, Flores Sanchez J, Ericsson CD, Mendiola Gomez J, DuPont MW, Cruz Luna A et al.| title=Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. | journal=Am J Med | year= 1990 | volume= 88 | issue= 6A | pages= 15S-19S | pmid=2192553 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2192553  }} </ref>
-[[Loperamide]] should be avoided in patients with [[inflammatory]] or [[bloody diarrhea]] because of the relation between antimotility agents and prolonged [[fever]] in patients infected with [[Shigella]] and [[C. difficile]].<ref name="pmid4587313">{{cite journal| author=DuPont HL, Hornick RB| title=Adverse effect of lomotil therapy in shigellosis. | journal=JAMA | year= 1973 | volume= 226 | issue= 13 | pages= 1525-8 | pmid=4587313 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4587313  }} </ref>
+[[Loperamide]] should be avoided in patients with [[inflammatory]] or [[bloody diarrhea]] because of the relation between antimotility agents and prolonged [[fever]] in patients infected with [[Shigella]] and [[C. difficile]] (other potential causative agents of [[infectious diarrhea]]).<ref name="pmid4587313">{{cite journal| author=DuPont HL, Hornick RB| title=Adverse effect of lomotil therapy in shigellosis. | journal=JAMA | year= 1973 | volume= 226 | issue= 13 | pages= 1525-8 | pmid=4587313 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4587313  }} </ref>
-====Bismuth Subsalicylate====
+* '''Bismuth Subsalicylate'''
 [[Bismuth subsalicylate]] may alleviate [[symptoms]] such as: [[nausea]], [[diarrhea]] and [[abdominal pain]].<ref name="pmid330307">{{cite journal| author=DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB| title=Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. | journal=Gastroenterology | year= 1977 | volume= 73 | issue= 4 Pt 1 | pages= 715-8 | pmid=330307 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=330307  }} </ref> It was also shown to decrease stool output in pediatric patients.<ref name="pmid8487823">{{cite journal| author=Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, León-Barúa R, Sarabia-Arce S, Campos-Sánchez M et al.| title=A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. | journal=N Engl J Med | year= 1993 | volume= 328 | issue= 23 | pages= 1653-8 | pmid=8487823 | doi=10.1056/NEJM199306103282301 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8487823  }} </ref>
-==Antibiotic Treatment==
+===Antibiotic Therapy===
-[[Antibiotics]] are not recommended for uncomplicated [[salmonellosis]] because they prolong shedding of the [[bacteria]], typically do not alleviate the [[diarrhea]], and have been associated with relapse.<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name="pmid1616214">{{cite journal| author=Wiström J, Jertborn M, Ekwall E, Norlin K, Söderquist B, Strömberg A et al.| title=Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. | journal=Ann Intern Med | year= 1992 | volume= 117 | issue= 3 | pages= 202-8 | pmid=1616214 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1616214  }} </ref><ref name="pmid1898630">{{cite journal| author=Neill MA, Opal SM, Heelan J, Giusti R, Cassidy JE, White R et al.| title=Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. | journal=Ann Intern Med | year= 1991 | volume= 114 | issue= 3 | pages= 195-9 | pmid=1898630 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1898630  }} </ref> [[Antibiotic]] therapy is only indicated for patients with severe cases of the disease, and for those with risk factors for extra-intestinal [[infection]], after blood and fecal cultures have been obtained. Risk groups for the development of extra-intestinal manifestations include:<ref name="pmid11170916">{{cite journal| author=Hohmann EL| title=Nontyphoidal salmonellosis. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 2 | pages= 263-9 | pmid=11170916 | doi=10.1086/318457 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170916  }} </ref><ref name="pmid25136336">{{cite journal| author=Gal-Mor O, Boyle EC, Grassl GA| title=Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ. | journal=Front Microbiol | year= 2014 | volume= 5 | issue=  | pages= 391 | pmid=25136336 | doi=10.3389/fmicb.2014.00391 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25136336  }} </ref>
+====Indications====
+[[Antibiotics]] are not recommended for uncomplicated [[salmonellosis]] because they prolong shedding of the [[bacteria]], typically do not alleviate the [[diarrhea]], and have been associated with relapse.<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name="pmid1616214">{{cite journal| author=Wiström J, Jertborn M, Ekwall E, Norlin K, Söderquist B, Strömberg A et al.| title=Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. | journal=Ann Intern Med | year= 1992 | volume= 117 | issue= 3 | pages= 202-8 | pmid=1616214 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1616214  }} </ref><ref name="pmid1898630">{{cite journal| author=Neill MA, Opal SM, Heelan J, Giusti R, Cassidy JE, White R et al.| title=Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. | journal=Ann Intern Med | year= 1991 | volume= 114 | issue= 3 | pages= 195-9 | pmid=1898630 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1898630  }} </ref> [[Antibiotic]] therapy is only indicated for patients with severe cases of the disease, and for those with risk factors for extra-intestinal [[infection]], after blood and fecal cultures have been obtained. ''Risk groups for the development of severe disease, and extra-intestinal manifestations include:''<ref name="pmid11170916">{{cite journal| author=Hohmann EL| title=Nontyphoidal salmonellosis. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 2 | pages= 263-9 | pmid=11170916 | doi=10.1086/318457 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170916  }} </ref><ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name="pmid25136336">{{cite journal| author=Gal-Mor O, Boyle EC, Grassl GA| title=Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ. | journal=Front Microbiol | year= 2014 | volume= 5 | issue=  | pages= 391 | pmid=25136336 | doi=10.3389/fmicb.2014.00391 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25136336  }} </ref>
 *Infants and elderly
 *Patients with [[pernicious anemia]]
-*Patients taking H2 antagonists and [[antacids]]
+*Patients taking [[H2 antagonist]]s and [[antacids]]
 *Changes in [[endogenous]] bowel flora, in:
 **Surgery
@@ Line 39: / Line 42: @@
 *[[HIV infection]]
 *[[Malignancy]]
+*[[Valvular heart disease]]
 *Rheumatological diseases
 *Blockage of [[reticuloendothelial]] system
+*Transplant recipients
 *[[Immunosuppressive]] therapy
+*Lymphoprolipherative disease
+*[[Hemoglobinopathies]]
+*[[Prosthetic]] devices, such as artificial [[joints]]
 [[Antibiotic]] treatment may be indicated in cases when rapid interruption of fecal shedding of the bacteria is required to avoid [[outbreaks]] in institutions.<ref name="pmid2292544">{{cite journal| author=Lightfoot NF, Ahmad F, Cowden J| title=Management of institutional outbreaks of Salmonella gastroenteritis. | journal=J Antimicrob Chemother | year= 1990 | volume= 26 Suppl F | issue=  | pages= 37-46 | pmid=2292544 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2292544  }} </ref>
+===Antimicrobial regimen===
+:* 1. '''Salmonellosis in immunocompetent hosts'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+::* 1.1 '''Gastroenteritis'''
+:::* Antimicrobial therapy is usually not recommended for uncomplicated diarrheal illness.
+:::* 1.1.1 '''Indications for antimicrobial therapy'''
+::::* severedisease,
+::::* Age > 50 yrs
+::::* Prosthesis
+::::* Presence of valvular heart disease
+::::* Severe atherosclerosis
+::::* Cancer
+::::* Uremia
+::::* Immunosuppression
+:::* 1.1.2 Treatment regimens
+::::* Preferred regimen (1): [[TMP-SMX]] DS PO bid for 5-7 days
+::::* Preferred regimen (2): [[Ciprofloxacin]] 500 mg PO bid for 5-7 days
+::::* Preferred regimen (3): [[Ceftriaxone]] 2 g IV q24h for 5-7 days
+::* 1.2 '''Typhoid fever'''<ref>{{Cite web | title = TYPHOID FEVER | url = http://www.nejm.org/doi/pdf/10.1056/NEJMra020201}}</ref>
+:::* 1.2.1 '''Uncomplicated typhoid'''
+::::* Preferred regimen (1) (fully susceptible): [[Fluoroquinolone]] (e.g., [[Ofloxacin]] 15 mg/kg PO qd for 5–7 days)
+::::* Preferred regimen (2) (multi drug-resistant): [[Fluoroquinolone]] ([[Ofloxacin]] 15 mg/kg PO qd for 5–7 days)
+::::* Preferred regimen (3) (quinolone-resistant): [[Azithromycin]] 8–10 mg/kg  PO qd for 7 days
+::::* Preferred regimen (4) (quinolone-resistant): [[Fluoroquinolone]] 20 mg/kg PO qd for 10-14 days
+::::* Alternative regimen (1) (fully susceptible): [[Chloramphenicol]] 50–75 mg/kg PO qd for 14-21 days
+::::* Alternative regimen (2) (fully susceptible): [[Amoxicillin]] 75–100 mg/kg PO qd for 14 days
+::::* Alternative regimen (3) (fully susceptible): [[Trimethoprim–Sulfamethoxazole]], 8 mg/kg ([[trimethoprim]])– 40 mg/kg ([[sulfamethoxazole]]) PO qd for 14 days
+::::* Alternative regimen (4) (multi drug-resistant): [[Azithromycin]] 8–10 mg/kg PO for 7 days
+::::* Alternative regimen (5) (multi drug-resistant): Third-generation cephalosporin, e.g., [[Cefixime]] 20 mg/kg PO qd for 7-14 days
+::::* Alternative regimen (6) (quinolone-resistant): Third-generation cephalosporin, e.g., [[Cefixime]] 20 mg/kg PO qd for 7-14 days
+:::* 1.2.2 '''Severe typhoid'''
+::::* Preferred regimen (1) (fully susceptible): [[Fluoroquinolone]] (e.g., [[Ofloxacin]] 15 mg/kg IV qd for 10-14 days)
+::::* Preferred regimen (2) (multi drug-resistant): [[Fluoroquinolone]] ([[Ofloxacin]] 15 mg/kg IV qd for 10-14 days)
+::::* Preferred regimen (3) (quinolone-resistant): [[Ceftriaxone]] 60 mg/kg IV qd for 10-14 days
+::::* Preferred regimen (4) (quinolone-resistant): [[Cefotaxime]] 80 mg/kg IV qd for 10-14 days
+::::* Alternative regimen (1) (fully susceptible): [[Chloramphenicol]] 100 mg/kg PO qd for 14-21 days
+::::* Alternative regimen (2) (fully susceptible): [[Ampicillin]] 100 mg/kg PO qd for 14-21 days
+::::* Alternative regimen (3) (fully susceptible): [[Trimethoprim–Sulfamethoxazole]], 8 mg/kg ([[trimethoprim]])– 40 mg/kg ([[sulfamethoxazole]]) IV qd for 10-14 days
+::::* Alternative regimen (4) (multi drug-resistant): [[Ceftriaxone]] 60 mg/kg IV qd for 10-14 days
+::::* Alternative regimen (5) (multi drug-resistant): [[Cefotaxime]] 80 mg/kg IV qd for 10-14 days
+::::* Alternative regimen (6) (quinolone-resistant): [[Fluoroquinolone]] 20 mg/kg IV qd for 10-14 days
+::* 1.3 '''Non-typhoid (serious infection)'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::* Preferred regimen (1): [[Cephalosporin|3rd generation cephalosporin]] ([[Ceftriaxone]]/[[Cefotaxime]])
+:::* Preferred regimen (2): [[Fluoroquinolone]] ([[Ciprofloxacin]], [[Levofloxacin]])
+::* 1.4 '''Bacteremia'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::* Preferred regimen (1): [[Ceftriaxone]] 2 g IV q24h
+:::* Preferred regimen (2): [[Cefotaxime]] 2 g IV q6-8h for 7-14 days
+:::* Preferred regimen (3): [[Ciprofloxacin]] 400 mg IV q12h for 7-14 days
+::* 1.5 '''Vascular prosthesis infection'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::* Preferred regimen (1): [[Ceftriaxone]]
+:::* Preferred regimen (2): [[Cefotaxime]]
+:::* Preferred regimen (3): [[Ciprofloxacin]] 400 mg IV q12h for 6 weeks
+::* 1.6 '''Osteomyelitis'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::* Preferred regimen (1): [[Ceftriaxone]] 2 g IV q24h
-For the cases where [[antibiotics]] are indicated, treatment should include one of the following:<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref>
+:::* Preferred regimen (2): [[Cefotaxime]] 2 g IV q6-8h
-===Trimethropim-Sulfamethoxazole===
-*Indicated in children and cases when susceptibility is suspected.
+:::* Preferred regimen (3): [[Ciprofloxacin]] 750 mg PO bid for ≥ 4 weeks
-*For 5 to 7 days
+::* 1.7 '''Arthritis'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
-===Fluoroquinolone===
+:::* Preferred regimen (1): [[Ceftriaxone]] 2 g IV q24h
-*For 5 to 7 days
-===Ceftriaxone===
+:::* Preferred regimen (2): [[Cefotaxime]] 2 g IV q6-8h for 6 weeks
-*100 mg/Kg body weight/day in 1 or 2 doses.
+::* 1.8 '''Endocarditis'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::* Preferred regimen (1): [[Ceftriaxone]] 2 g IV q24h
+:::* Preferred regimen (2): [[Cefotaxime]] 2 g IV q6-8h for 6 weeks
+::* 1.9 '''UTI'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::*Preferred regimen (1): [[Ceftriaxone]]
+:::*Preferred regimen (2): [[Cefotaxime]]
+:::*Preferred regimen (3): [[Ciprofloxacin]] IV for 1-2 weeks {{then}} ([[Ciprofloxacin|oral Ciprofloxacin]] {{or}} [[TMP-SMX]] for 6 weeks)
+::* 1.10 '''Carrier state'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
+:::* Preferred regimen (1): [[Ciprofloxacin]] 500 mg PO bid for 4-6 weeks
+:::* Preferred regimen (2): [[TMP-SMX]] 1DS bid PO for 6 weeks
+:::* Preferred regimen (3): [[Amoxicillin]] 500 mg PO for 6 weeks
+::* 2. '''Salmonellosis in immunocompromised hosts'''
+:::* 2.1 '''HIV and salmonellosis'''<ref>{{Cite web | title = Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents | url = https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultOITablesOnly.pdf}}</ref>
+::::* 2.1.1 Gastroenteritis
+:::::* Preferred regimen: [[Ciprofloxacin]] 500-750 mg PO bid or 400 mg IV q12h, if susceptible
+:::::* Alternative regimen (1): [[Levofloxacin]] 750 mg PO/IV q24h
+:::::* Alternative regimen (2): [[Moxifloxacin]] 400 mg PO/IV q24h
+:::::* Alternative regimen (3): [[TMP]] 160 mg {{and}} [[sulfamethoxazole|SMX]] 800 mg PO/IV q12h
+:::::* Alternative regimen (4): [[Ceftriaxone]] 1 g IV q24h
+:::::* Alternative regimen (5): [[Cefotaxime]] 1 g IV q8h
+:::::* Duration of treatment for gastroenteritis without bacteremia
+::::::* If CD4 count ≥ 200 cells/μL: Duration of treatment is 7–14 days
+::::::* If CD4 count < 200 cells/μL: Duration of treatment is 2–6 weeks
+:::::* Duration of treatment for gastroenteritis with bacteremia
+::::::* If CD4 count ≥ 200/μL: Duration of treatment is 14 days; longer duration if bacteremia persists or if the infection is complicated (e.g., if metastatic foci of infection are present)
+::::::* If CD4 count < 200 cells/μL: Duration of treatment is 2–6 weeks
+:::::* Note (1): Secondary prophylaxis should be considered for
+::::::* Patients with recurrent Salmonella gastroenteritis with or without bacteremia
+::::::* Patients with CD4 < 200 cells/μL with severe diarrhea
+:* 1. '''Salmonella bacteremia treatment'''
+::* Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h {{and}} [[Ceftriaxone]] 1 to 2 g IV q12-24h<ref> {{cite book | last =   Goldman | first = Lee  | title = Goldman's Cecil Medicine, Twenty-Fourth Edition
+ | publisher = Saunders, an imprint of Elsevier Inc. | location =  | year = 2012 | isbn = 978-1-4377-1604-7}}</ref>
+:* 2.'''When the salmonellae are known to be susceptible'''
+::* Preferred regimen: [[Ampicillin]] 1 to 2 g IV  q4-6h
+::* Preferred regimen: [[Trimethoprim-sulfamethoxazole]] 8 mg/kg/day PO
+\====Recommended Agents====
+For the cases where [[antibiotics]] are indicated, treatment should include one of the following:<ref name="pmid14702426">{{cite journal| author=Thielman NM, Guerrant RL| title=Clinical practice. Acute infectious diarrhea. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 1 | pages= 38-47 | pmid=14702426 | doi=10.1056/NEJMcp031534 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14702426  }} </ref><ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref>
+*'''Trimethoprim-Sulfamethoxazole'''
+Indicated for children, and when susceptibility is suspected
+{|  style="border: 0px; margin: 3px;" align=center  width="600px"
+|-
+! style="background: #4479BA; padding: 2px 2px;" rowspan=1 | {{fontcolor|#FFFFFF|Children}}
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | 5 mg/kg ([[trimethoprim]]) + 25 mg/kg ([[sulfamethoxazole]]) twice/day, during 3 days
+|-
+! style="background: #4479BA; padding: 2px 2px;" rowspan=1 | {{fontcolor|#FFFFFF|Adults}}
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | 160 mg ([[trimethoprim]]) + 800 mg ([[sulfamethoxazole]]) twice/day, during 3 days
+|}
+<br>
+*'''Fluoroquinolones'''
+{| style="border: 0px; margin: 3px;" align=center  width="600px"
+|-
+! style="background: #4479BA; padding: 2px 2px;" rowspan=1 | {{fontcolor|#FFFFFF|Adults}}
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | [[Ciprofloxacin]] - 500 mg PO twice/day, during 1 to 3 days
+|-
+|style="padding: 5px 5px; background: #F5F5F5;" | [[Norfloxacin]] - 400 mg PO twice/day, during 1 to 3 days
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | [[Levofloxacin]] - 500 mg PO once/day, during 1 to 3 days
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | [[Ofloxacin]] - 300 mg twice/day, during 1 to 3 days
+|}
+<br>
+*'''Ceftriaxone'''
+{| style="border: 0px; margin: 3px;" align=center  width="600px"
+|-
+! style="background: #4479BA; padding: 2px 2px;" rowspan=1 | {{fontcolor|#FFFFFF|Children <12 years old}}
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | 50-75 mg/kg body weight/day in 1 or 2 doses
+|-
+! style="background: #4479BA; padding: 2px 2px;" rowspan=1 | {{fontcolor|#FFFFFF|Adults}}
+|-
+| style="padding: 5px 5px; background: #F5F5F5;" | 100 mg/Kg body weight/day in 1 or 2 doses
+|}
+For [[immunocompromised]] patients, the duration of the [[antibiotic treatment]] described above should be prolonged for 14 days, or longer in case of relapse.<ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref>
 ==Multidrug Resistance==
@@ Line 58: / Line 208: @@
 ==Follow Up==
-Fecal cultures are not indicated for patient follow-up after uncomplicated cases of [[salmonellosis]], irrespectively to the treatment administrated. The results tend to be intermittently positive for a long period of time, and do not show any utility in an [[asymptomatic]] patient.<ref name="pmid11170916">{{cite journal| author=Hohmann EL| title=Nontyphoidal salmonellosis. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 2 | pages= 263-9 | pmid=11170916 | doi=10.1086/318457 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170916  }} </ref><ref name="pmid6377442">{{cite journal| author=Buchwald DS, Blaser MJ| title=A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. | journal=Rev Infect Dis | year= 1984 | volume= 6 | issue= 3 | pages= 345-56 | pmid=6377442 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6377442  }} </ref>
+Fecal cultures are not indicated for patient follow-up after uncomplicated cases of [[salmonellosis]], irrespectively to the treatment administrated. The results tend to be intermittently positive for a long period of time, and do not show any utility in [[asymptomatic]] patients.<ref name="pmid11170916">{{cite journal| author=Hohmann EL| title=Nontyphoidal salmonellosis. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 2 | pages= 263-9 | pmid=11170916 | doi=10.1086/318457 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170916  }} </ref><ref name="pmid6377442">{{cite journal| author=Buchwald DS, Blaser MJ| title=A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. | journal=Rev Infect Dis | year= 1984 | volume= 6 | issue= 3 | pages= 345-56 | pmid=6377442 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6377442  }} </ref>
 ==References==
@@ Line 65: / Line 215: @@
 [[Category:Foodborne illnesses]]
 [[Category:Zoonoses]]
+[[Category:Disease]]
-[[Category:Disease]]
-[[Category:Infectious disease]]
 [[Category:Emergency medicine]]
 [[Category:Intensive care medicine]]
+[[Category:Infectious Disease Project]]
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}